akouos gene therapy hearing loss treatment

Akouos More Than Doubles Original IPO Goal, Raises $213M in First Day of Trading

BOSTON, MASSACHUSSETTS — After originally filing for an initial public offer (IPO) with the US Securities and Exchange Commission (SEC) earlier this month, eyeing a $100M IPO, gene therapy startup Akouos significantly exceeded its original expectations on Friday by raising $213M. The company sold 12.5 million shares for $17 each, above its anticipated range of…

Read More
akouos gene therapy hearing loss treatment

Akouos Files for $100M IPO to Accelerate Gene Therapy Hearing Loss Treatment Program

BOSTON, MASSACHUSSETTS – Akouos, a precision genetic medicine company developing gene therapies to restore and preserve hearing, has filed for an initial public offer (IPO) with the Securities and Exchange Commission, eyeing a $100M IPO. The filing comes barely 3 months after he company completed its Series B funding round, which raised $105M. The company’s…

Read More
akouos gene therapy hearing loss treatment

Akouos Closes $105 Million Series B Financing; Announces New Appointments to Board of Directors

BOSTON, MASSACHUSSETTS — Akouos, Inc., a precision genetic medicine company developing potential gene therapies to restore, improve or preserve hearing, today announced it has raised $105 million in an oversubscribed Series B financing. The Series B financing was led by Pivotal bioVenture Partners, with participation from new investors Cormorant Asset Management, Cowen Healthcare Investments, EcoR1…

Read More
gene therapy for hearing loss

Akouos Discloses Lead Program, AK-OTOF, a Potential Gene Therapy Treatment for Sensorineural Hearing Loss

BOSTON, MASS. – Akouos, a precision genetic medicine company developing gene therapies to restore and preserve hearing, today disclosed its lead program, AK-OTOF, a gene therapy focused on restoring hearing in individuals with sensorineural hearing loss due to mutations in the otoferlin (OTOF) gene. Normal otoferlin function enables the sensory cells of the ear (hair…

Read More
akouos gene therapy hearing loss treatment

Akouos Announces New Executive Leadership Team Appointments

BOSTON, MASSACHUSETTS — Akouos, a precision genetic medicine company developing gene therapies to restore and preserve hearing, announced two key leadership appointments this week. Gregory Robinson, Ph.D., has joined the company as chief scientific officer, and co-founder Michael McKenna, M.D., expands his role to full-time chief medical officer.   Using Gene Therapy to Restore and…

Read More

Frequency Therapeutics Launches US Clinical Trials of Hearing Loss Drug; Akouos Raises $50M for Gene Therapy R&D

Biotech startup, Frequency Therapeutics, announced today that the first patients have been treated in a Phase 1/2 clinical trial to evaluate the company’s investigative compound FX-322, the company’s lead Progenitor Cell Activation (PCA) candidate for hearing restoration. The randomized, double-blind, placebo-controlled trial will assess the safety of FX-322 given by intratympanic administration in adult patients…

Read More
akouos gene therapy hearing loss treatment

Boston-Based Biotech, Akouos, Nets $7.5M Investment to “Restore and Preserve Hearing”

BOSTON, MASSACHUSETTS — Biotechnology startup, Akouos, announced that it has raised $7.5 million in seed funding. The company, which was spun out of the Harvard Innovation Labs, is developing novel therapies and delivery systems to prevent hearing loss and restore hearing in genetically defined populations. New Enterprise Associates (NEA), who led the seed funding along…

Read More